Switch theme
Sign up to access all valuation multiples
Orchestra BioMed Holdings Inc is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Its partnership-enabled business model focuses on forging strategic collaborations with medical device companies to drive the commercialization of the products it develops. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension and Virtue Sirolimus AngioInfusionBalloon (SAB) for the treatment of atherosclerotic artery disease.
2018
70
LTM Revenue $2.8M
LTM EBITDA -$70.0M
$76.5M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Orchestra BioMed has a last 12-month revenue (LTM) of $2.8M and a last 12-month EBITDA of -$70.0M.
In the most recent fiscal year, Orchestra BioMed achieved revenue of $2.6M and an EBITDA of -$64.0M.
Orchestra BioMed expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Orchestra BioMed valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $2.8M | XXX | $2.6M | XXX | XXX | XXX |
| Gross Profit | $2.7M | XXX | $2.4M | XXX | XXX | XXX |
| Gross Margin | 94% | XXX | 92% | XXX | XXX | XXX |
| EBITDA | -$70.0M | XXX | -$64.0M | XXX | XXX | XXX |
| EBITDA Margin | -2482% | XXX | -2426% | XXX | XXX | XXX |
| EBIT | -$70.7M | XXX | -$64.3M | XXX | XXX | XXX |
| EBIT Margin | -2507% | XXX | -2437% | XXX | XXX | XXX |
| Net Profit | -$68.0M | XXX | -$61.0M | XXX | XXX | XXX |
| Net Margin | -2412% | XXX | -2313% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Orchestra BioMed's stock price is $3.
Orchestra BioMed has current market cap of $110M, and EV of $76.5M.
See Orchestra BioMed trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $76.5M | $110M | XXX | XXX | XXX | XXX | $-1.81 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Orchestra BioMed has market cap of $110M and EV of $76.5M.
Orchestra BioMed's trades at 29.0x EV/Revenue multiple, and -1.2x EV/EBITDA.
Equity research analysts estimate Orchestra BioMed's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Orchestra BioMed has a P/E ratio of -1.6x.
See valuation multiples for Orchestra BioMed and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $110M | XXX | $110M | XXX | XXX | XXX |
| EV (current) | $76.5M | XXX | $76.5M | XXX | XXX | XXX |
| EV/Revenue | 27.1x | XXX | 29.0x | XXX | XXX | XXX |
| EV/EBITDA | -1.1x | XXX | -1.2x | XXX | XXX | XXX |
| EV/EBIT | -1.1x | XXX | -1.2x | XXX | XXX | XXX |
| EV/Gross Profit | 28.8x | XXX | n/a | XXX | XXX | XXX |
| P/E | -1.6x | XXX | -1.8x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -1.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialOrchestra BioMed's last 12 month revenue growth is 14%
Orchestra BioMed's revenue per employee in the last FY averaged $38K, while opex per employee averaged $1.0M for the same period.
Orchestra BioMed's rule of 40 is -1842% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Orchestra BioMed's rule of X is -2448% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Orchestra BioMed and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 14% | XXX | 13% | XXX | XXX | XXX |
| EBITDA Margin | -2482% | XXX | -2426% | XXX | XXX | XXX |
| EBITDA Growth | 11% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -1842% | XXX | -2412% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -2448% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $38K | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.0M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 1623% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 2530% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Orchestra BioMed acquired XXX companies to date.
Last acquisition by Orchestra BioMed was XXXXXXXX, XXXXX XXXXX XXXXXX . Orchestra BioMed acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Orchestra BioMed founded? | Orchestra BioMed was founded in 2018. |
| Where is Orchestra BioMed headquartered? | Orchestra BioMed is headquartered in United States of America. |
| How many employees does Orchestra BioMed have? | As of today, Orchestra BioMed has 70 employees. |
| Who is the CEO of Orchestra BioMed? | Orchestra BioMed's CEO is Mr. David P. Hochman. |
| Is Orchestra BioMed publicy listed? | Yes, Orchestra BioMed is a public company listed on NAS. |
| What is the stock symbol of Orchestra BioMed? | Orchestra BioMed trades under OBIO ticker. |
| When did Orchestra BioMed go public? | Orchestra BioMed went public in 2023. |
| Who are competitors of Orchestra BioMed? | Similar companies to Orchestra BioMed include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of Orchestra BioMed? | Orchestra BioMed's current market cap is $110M |
| What is the current revenue of Orchestra BioMed? | Orchestra BioMed's last 12 months revenue is $2.8M. |
| What is the current revenue growth of Orchestra BioMed? | Orchestra BioMed revenue growth (NTM/LTM) is 14%. |
| What is the current EV/Revenue multiple of Orchestra BioMed? | Current revenue multiple of Orchestra BioMed is 27.1x. |
| Is Orchestra BioMed profitable? | Yes, Orchestra BioMed is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Orchestra BioMed? | Orchestra BioMed's last 12 months EBITDA is -$70.0M. |
| What is Orchestra BioMed's EBITDA margin? | Orchestra BioMed's last 12 months EBITDA margin is -2482%. |
| What is the current EV/EBITDA multiple of Orchestra BioMed? | Current EBITDA multiple of Orchestra BioMed is -1.1x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
